US Patent

US10842751 — Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine

Formulation · Assigned to Merck Sharp and Dohme LLC · Expires 2036-11-29 · 11y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate, and lamivudine for treating HIV infection.

USPTO Abstract

The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.

Drugs covered by this patent

Patent Metadata

Patent number
US10842751
Jurisdiction
US
Classification
Formulation
Expires
2036-11-29
Drug substance claim
No
Drug product claim
Yes
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.